Skip to content

Joint Pain Occurring During Anti-TNF Therapy in Chronic Inflammatory Bowel Disease

Joint Pain Occurring During Anti-TNF Therapy in Chronic Inflammatory Bowel Disease

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02899871
Acronym
ArthralgieMICI
Enrollment
99
Registered
2016-09-14
Start date
2014-09-30
Completion date
2016-10-31
Last updated
2018-08-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases

Keywords

joint pain

Brief summary

IBD (inflammatory bowel disease) are associated with various types of joint manifestations, especially inflammatory. Patients with IBD treated with anti-TNF commonly report joint symptoms, with variable expressions and aetiologies, possibly responsible for impaired quality of life, and possibly leading to discontinuation of an effective and validated treatment.

Interventions

OTHERdiagnosis of joint

The diagnosis of joint pain will be established by a rheumatologist and completed: * If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI). * serum assays of the anti-TNF administered, as well as screening for associated antibodies.

Sponsors

Centre Hospitalier Universitaire, Amiens
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Males or females over the age of 18 years at the time of inclusion * Patients with IBD (Crohn's disease or ulcerative colitis), diagnosed by a set of compatible clinical (chronic diarrhoea, haematochezia, anoperineal lesions, etc.), laboratory, histological and endoscopic arguments. Patients will be included regardless of the severity of their disease, its clinical course, the type of lesions, and the presence or absence of associated manifestations. * Patients treated with anti-TNF: infliximab or adalimumab. * Informed patients not refusing to participate. * Patients covered by French national health insurance.

Exclusion criteria

* Patients under the age of 18 years at the time of inclusion. * Patients previously treated with anti-TNF, but no longer treated with anti-TNF at the time of inclusion. * Protected majors (under permanent or temporary guardianship).

Design outcomes

Primary

MeasureTime frameDescription
Diagnosis of joint pain1 yearpresence or absence : The diagnosis of joint pain will be established by a rheumatologist and completed: * If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI). * serum assays of the anti-TNF administered, as well as screening for associated antibodies.

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026